VANGUARD®crLyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs

doi:10.1016/j.jvacx.2020.100079

Paper

VANGUARD®crLyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs

Published Oct 9, 2020 · R. Marconi, D. Garcia‐Tapia, Jacquelien D Hoevers

Vaccine: X

Q1 SJR score

29

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

VANGUARD®crLyme is a highly effective and immunogenic canine Lyme disease vaccine, providing protection against infection and preventing clinical manifestations and histopathological changes in dogs.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

VANGUARD®crLyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs

References

Citations